Differentiating Pancreatitis from Pancreatic Cancer on Imaging

Initial Imaging Strategy

The American Gastroenterological Association recommends starting with abdominal ultrasound to identify liver metastases, which would immediately distinguish cancer from pancreatitis, with 80-95% sensitivity for detecting pancreatic carcinoma 1, 3

The European Society of Gastrointestinal Endoscopy suggests that MRCP provides detailed ductal images and may clarify diagnostic uncertainty between chronic pancreatitis versus cancer without the risk of ERCP-induced pancreatitis 1
MRI with gadolinium combined with MRCP has specific advantages over CT for detecting small hepatic metastases and peritoneal metastases, according to the National Comprehensive Cancer Network 2

The presence of liver metastases definitively excludes isolated pancreatitis, as stated by the American College of Radiology 1, 2
Vascular invasion or encasement of major vessels is a feature favoring cancer, according to the European Society for Medical Oncology 1, 4
Lymph node metastases are also a feature favoring cancer, as stated by the National Comprehensive Cancer Network 1

EUS is superior to spiral CT, MR, or PET in detecting small tumors and can localize lymph node metastases or vascular tumor infiltration with high sensitivity, according to the American Society for Gastrointestinal Endoscopy 4
EUS-guided fine-needle aspiration is safe and highly accurate for tissue diagnosis, as stated by the European Society of Gastrointestinal Endoscopy 5

Pancreatic cancer should be excluded during investigation of any unexplained episode of acute pancreatitis, according to the American Gastroenterological Association 6, 3
In patients with known chronic pancreatitis, underlying carcinoma should be strongly considered in the absence of another recognized etiology for pancreatitis, as stated by the National Comprehensive Cancer Network 6

Histological confirmation is mandatory in non-resectable cases, which suspected liver metastases would indicate, according to the National Comprehensive Cancer Network 2, 5
EUS-guided FNA is preferred over percutaneous approaches due to lower bleeding risk and no peritoneal seeding risk, as stated by the American Society for Gastrointestinal Endoscopy 5, 7
A negative biopsy should never delay appropriate treatment when clinical suspicion remains high, according to the European Society for Medical Oncology 4, 5